Patent Assignment
Reel/Frame 036328/0122
Nunc Pro Tunc Assignment
Recorded: 2015-08-14
Pages: 8
Assignor
OPTIMER PHARMACEUTICALS LLC
Executed: 2015-07-28
Assignee
MERCK SHARP & DOHME CORP.
126 EAST LINCOLN AVENUE, RAHWAY, NEW JERSEY, 07065
Covered Properties
(26)
Tiacumicin Production
Novel Antibacterial Agents
Polymorphic Crystalline Forms of Tiacumicin B
18-Membered Macrocycles and Analogs Thereof
Macrolide Polymorphs, Compositions Comprising Such Polymorphs, and Methods of Use and Manufacture Thereof
Antibiotic Macrocycle Compounds and Methods of Mnaufacture and Use Thereof
Macrolide Polymorphs, Compositions Comprising Such Polymorphs, and Methods of Use and Manufacture Thereof
Novel Antibacterial Agents
Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs, and Methods of Use and Manufacture Thereof
18-Membered Macrocycles and Analogs Thereof
Macrocyclic Polymorphs, Compositions Comprising Such Polymorphs and Methods of Use and Manufacture Thereof
Novel Antibacterial Agents
Antibiotic Macrocycle Compounds and Methods of Manufacture and Use Thereof
Compositions of Stable Tiacumicins
Application:
13/416,768 →
Publication:
US 2013/0065844
Treatment of Disease Associated with the Use of Antibiotics
Application:
13/457,216 →
Publication:
US 2013/0274175
Tiacumicin Production
Novel Antibacterial Agents
Method of Treating Clostridium Difficile-Associated Diarrhea
Application:
13/723,881 →
Publication:
US 2014/0107054
Antibiotic Macrocycle Compounds and Methods of Manufacture and Use Thereof
18-Membered Macrocycles and Analogs Thereof
Application:
13/838,634 →
Publication:
US 2013/0252913
Macrolide Polymorphs, Compositions Comprising Such Polymorphs, and Methods of Use and Manufacture Thereof
Application:
13/839,299 →
Publication:
US 2013/0252914
Treatment of Clostridium Difficile Infection in Patients Undergoing Antibiotic Therapy
Application:
13/930,969 →
Publication:
US 2013/0331347
Methods of Treating Recurring Bacterial Infection
Application:
13/930,994 →
Publication:
US 2014/0315838
Tiacumicin Production
Application:
14/281,496 →
Publication:
US 2014/0296498
Prevention of Clostridium Difficile Infection in High Risk Patients
Application:
14/385,744 →
Publication:
US 2015/0157653
Treatment of Clostridium Difficile Infection in High Risk Patients
Application:
14/542,543 →
Publication:
US 2015/0141356
Related Assignments
(5)
Other recorded transfers of the patents in this record — the chain of ownership.
Security Agreement
Nov 13, 2013
From: OPTIMER PHARMACEUTICALS, INC.; TRIUS THERAPEUTICS INC.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 031628/0850 →
Release of Security Interest
Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: TRIUS THERAPEUTICS, INC.; OPTIMER PHARMACEUTICALS, INC.
Reel/Frame 036178/0175 →
Change of Name
Aug 12, 2015
From: OPTIMER PHARMACEUTICALS, INC.
To: OPTIMER PHARMACEUTICALS LLC
Reel/Frame 036333/0793 →
Assignment of Assignor's Interest
Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
Merger
Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →